Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Yunfu Cui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7393-1680; OpenAlex author ID A5084257557. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper

Papers 9

  1. Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.89788↗
  2. Exosomal miRNAs in the microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.cca.2023.117360↗
  3. Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy. Co-author DOI 10.3389/fimmu.2023.1222719↗
  4. Characterization of tumor microenvironment and programmed death-related genes to identify molecular subtypes and drug resistance in pancreatic cancer. Last author DOI 10.3389/fphar.2023.1146280↗
  5. Transcriptional ITPR3 as potential targets and biomarkers for human pancreatic cancer. Last author DOI 10.18632/aging.204080↗
  6. Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity in vitro and in vivo through targeting the NF-κB signaling pathwa… Last author DOI 10.18632/aging.103327↗
  7. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 … Last author DOI 10.1016/j.bbrc.2018.12.088↗
  8. Tectonic 1 Is a Key Regulator of Cell Proliferation in Pancreatic Cancer. Co-author DOI 10.1089/cbr.2014.1778↗
  9. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines. First author DOI 10.7314/apjcp.2013.14.9.5243↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinlei Zou · 3 shared papers, 2023–2024 · strength 0.57
  2. Jianjun Gao · 3 shared papers, 2023–2024 · strength 0.57
  3. Yi Xu · 4 shared papers, 2019–2023 · strength 0.57
  4. Xiangyu Zhong · 3 shared papers, 2020–2023 · strength 0.51
  5. Liang Yu · 1 shared paper, 2023 · strength 0.31
  6. Daolin Ji · 2 shared papers, 2020–2022 · strength 0.25
  7. Wangyang Zheng · 2 shared papers, 2020–2022 · strength 0.25
  8. Pengcheng Kang · 2 shared papers, 2016–2020 · strength 0.18
  9. Haolin Bao · 1 shared paper, 2024 · strength 0.18
  10. Xiangyu Zhong · 1 shared paper, 2024 · strength 0.18
  11. Yue Yao · 1 shared paper, 2019 · strength 0.14
  12. Yao Liu · 1 shared paper, 2013 · strength 0.08
  13. Shiyong Zhao · 1 shared paper, 2016 · strength 0.07
  14. Xingming Jiang · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.